Literature DB >> 32435167

Bioinformatics Analysis of Domain 1 of HCV-Core Protein: Iran.

Behzad Dehghani1, Tayebeh Hashempour1, Zahra Hasanshahi1, Javad Moayedi1.   

Abstract

n class="Disease">Hepatitis C virus (HCV) infectionpan> is a n class="Chemical">serious global health problem and a cause of n class="Disease">chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Bioinformatics software has been an effective tool to study the HCV genome as well as core domains. Our research was based on employing several bioinformatics software applications to find important mutations in domain 1 of core protein in Iranian HCV infected samples from 2006 to 2017, and an investigation of general properties, B-cell and T-cell epitopes, modification sites, and structure of domain 1. Domain 1 sequences of 188 HCV samples isolated from 2006 to 2017, Iran, were retrieved from NCBI gene bank. Using several tools, all sequences were analyzed for determination of mutations, physicochemical analysis, B-cell epitopes prediction, T-cell and CTL epitopes prediction, post modification, secondary and tertiary structure prediction. Our analysis determined several mutations in some special positions (70, 90, 91, and 110) that are associated with HCC and hepatocarcinogenesis, efficacy of triple therapy and sustained virological response, and interaction between core and CCR6. Several B-cell, T-cell, and CTL epitopes were recognized. Secondary and tertiary structures were mapped fordomain1 and core proteins. Our study, as a first report, offered inclusive data about frequent mutation in HCV-core gene domain 1 in Iranian sequences that can provide helpful analysis on structure and function of domain 1 of the core gene. © Springer Nature B.V. 2019.

Entities:  

Keywords:  Bioinformatics; Core; Domain1; HCV

Year:  2019        PMID: 32435167      PMCID: PMC7223762          DOI: 10.1007/s10989-019-09838-y

Source DB:  PubMed          Journal:  Int J Pept Res Ther        ISSN: 1573-3149            Impact factor:   1.931


Introduction

n class="Disease">HCV infectionpan> is a n class="Chemical">serious global health problem and causes n class="Disease">chronic hepatitis, liver cirrhosis, and HCC (Akuta et al. 2007; Ajorloo et al. 2015; Alborzi et al. 2017, 2015; Moayedi et al. 2018; Hashempoor et al. 2018). It is estimated that 160 million people are infected worldwide (Lavanchy 2011). The prevalence rate of HCV infection is from 0.2 up to 40% in different countries, and this prevalence in Iran is 0.16% (Sefidi et al. 2013). Lack of an effective vaccine and therapeutic choices has leaded to the rapid growth of n class="Disease">HCV infection (Lauer anpan>d Walker 2001). n class="Species">HCVpan> has six ln class="Chemical">arge different genotypes (1–6) and 70 distinct subtypes (a, b, c, etc.) globally (Martro et al. 2011). Genotyping analysis showed 30–33% difference in each genotype, and in subtypes around 20–25% (Sefidi et al. 2013). According to the current investigations in Iran, the predominant n class="Species">HCV subtype is 1a, followed by 3a and 1b (Sefidi et al. 2013). n class="Species">HCVpan> is a positive-strand RNA virus encoding three structural components, the core protein, and two E1 and E2 envelope glycoproteins (Ajorloo et al. 2015). The core protein has mapan class="Chemical">ny confirmed roles: core binds RNA and DNA and has an important function in RNA packing. It has been determined that HCV-core is a nucleic acid chaperone similar to retroviral nucleocapsid (NC) proteins in act acting to rearrange HCV 3′UTR, resulting in RNA dimerization in vitro (Caval et al. 2011; Cristofari Gl; Ivanyi-Nagy et al. 2004; Steinmann et al. 2008). n class="Species">HCVpan>-core is a highly basic protein that forms the viral NC and has interactions with cellular proteins and signal transduction pathways. As a result of HCV-core and host cell interactions, core may have a function in persistent n class="Disease">infection and the pathogenesis of HCV liver disease (Polyak et al. 2006; Hashempour et al. 2015). Core protein consisted of n class="Chemical">three predicted domainpan>s: aa1-aa117 domain 1 (domain D1), aa117-aa177 domainpan> 2 (domainpan> D2), n class="Gene">and 177–191 domain 3 (domain D3) (Strosberg et al. 2010). Domain 1 copan class="Chemical">ntains frequent positively charged amino acids, and is involved in Rclass="Chemical">pan> class="Chemical">NA binding, promotes dimerization of the viral RNA, and has a significant role in NC formation and core envelopment by endosomal membranes (Ivanyi-Nagy et al. 2006). Several identified mutatiopan class="Chemical">ns in domain 1 are involved in the development of HCC and hepatocarcinogenesis, the efficacy of triple therapy, and interaction between core and CXCL6 (Akuta et al. 2007, 2010, 2011; Fishman et al. 2009; Ogata et al. 2002; Takahashi et al. 2001; Idrees and Ashfaq 2013). Humoral and cellular immupan class="Chemical">ne responses against HCV infections are inefficient and there is npan>o convincing explanation to unpan>derstand HCV immune pathogenesis (Gremion and Cerny 2005). However, HCV-specific IgM and IgG together were detected in acute infection. There are some outstanding proofs supporting a role for Abs in control of HCV infection and especially in reinfection (Cashman et al. 2014). Some researchers have described a rise in apan class="Chemical">nti-HCV humeral immunpan>e after immunclass="Chemical">pan>ization with core protein (Aghasadeghi et al. 2006). Other researchers have claimed that in acute HCV infection the titer of antibodies is very low, and delay in neutralizing antibody production is responsible for ineffective ability to prevent HCV infection (Netski et al. 2005). Other sources have introduced a large diversity of epitopes in n class="Species">HCV proteins as a possible way to escape the humoral response (Pavio and Lai 2003). Cellular immune respopan class="Chemical">nses have an important role in the clearance of HCV infection. Patients with cellular immune dysfunction like human immunodeficiency virus (HIV) have rapid HCV progression. Some researchers have claimed that this system promotes liver injury by cytolysis activity of infected cells. In spite of cellular immune responses, HCV often evades recognition and has the ability to persist (Ward et al. 2002). Several studies have described a number of pathways for papan class="Chemical">n class="Species">HCV to escape from cell responpan>ses, including impaired oligo-/mono-specific or no virus-specific CD4+ and CD8+, mutation of epitopes, weakness of proliferative capacity, and cytotoxicity and ability to secrete TNF-α and IFN-γ by n class="Gene">CD8+ T cells (Neumann-Haefelin et al. 2005). In addition, regulatory T cells (Tregs) induced by HCV infection have a significant role in the impaired activity of cellular immune response (Hashempour et al. 2015; Hashempoor et al. 2010). Bioinformatics tools are efficiepan class="Chemical">nt means to study viruses and different parts of the HCV genome like core domains (Idrees and Ashfaq 2013; Moattari et al. 2015; Dehghani et al. 2017; class="Chemical">pan> class="Chemical">Nezafat et al. 2018; Atapour et al. 2018; Sarvari et al. 2014; Behzad Dehghani and Zahra Hasanshahi 2019). Bioinformatics tools are efficient means to study viruses and different parts of the HCV genome like core domains. Many programs have been developed to analyze function, structures, and modification of core protein, providing a large amount of information about core domains and important mutation sites (Akuta et al. 2007, 2010, 2011). Current data are useful for prediction of n class="Disease">HCV disease developmenpan>t anclass="Chemical">pan>d treatment responpan>se. Inpan> this study, we employed several bioinpan>formatics tools to finpan>d important mutationpan>s inpan> domainpan> 1 of the core proteinpan>, genpan>eral properties of B-cell and T-cell epitopes, modificationpan> sites, and structure of domainpan> 1 inpan> n class="Disease">Iranian HCV infected samples from 2006 to 2017.

Materials and Methods

Sequence Alignment and Phylogenetic Tree

Domain 1 sepan class="Chemical">quences of 188 Iranian HCV samples and reference sequences of HCV genotypes that were registered in NCBI gene bank (http://www.ncbi.nlm.nih.gov/) from 2006 to 2017 were downloaded. Homology among sequences was determined using multiple sequence alignment available in CLC- sequence viewer software under the following parameters: gap open cost, 10; gap extension cost, 1.0; and very accurate progressive alignment algorithm. Also, phylogenetic trees were analyzed through CLUSTAL X software, version 1.81, by neighbor-joining times to confirm the reliability of phylogenetic trees. The accession numbers of all sequences are displayed in Table 1.
Table 1

The accession numbers of all 188 sequences that were used in this study

2006(16)DQ065821-DQ065836 and DQ202323
2012(1)JN129986
2013(84)KC118250-KC118333, KC118288
2014(28)KC285337-KC285362, JQ341409,KF218585,KC118320
2016(59)KT329291-KT329341, KU736828-KU736837
The accession numbers of all 188 sequences that were used in this study

Determination of Mutations

By consideripan class="Chemical">ng previous studies, several significant mutations that are involved in: 1-hepatocellular carcinoma, 2-viral response to triple therapy, and 3-the interaction between core and class="Chemical">pan> class="Gene">CXCL6, were determined. All sequences were compared to find mentioned mutations (Akuta et al. 2007; Fishman et al. 2009; Ogata et al. 2002).

Physico-chemical Analysis

General properties of domaipan class="Chemical">n 1 (genotype 1a) were determined by employing “Expasy’sProtParam” (http://expasy.org/tools/protparam.html) and ProtScale at (http://web.expasy.org/protscale/) (Gasteiger et al. 2005).

B-Cell Epitopes Prediction

Chou and Fasmapan class="Chemical">n, Karplus and Schulz, Kolaskar & Tongaonkar, Emini, Parker, and BepiPred methods at http://www.immuneepitope.org (http://tools.immuneepitope.org/tools/bcell/iedb_input) were run for prediction of B-Cell epitopes positions (Chou and Fasman 2009; Karplus and Schulz 1985; Emini et al. 1985; Parker et al. 1986; Larsen et al. 2006). On hydrophilicity, flexibility/mobility, accessibility, polarity, exposed surface apan class="Chemical">nd turns features by BcePred (http://www.imtech.res.in/raghava/bcepred) B-cell epitopes prediction were performed (Saha and Raghava 2004). ABCpred software (http://www.imtech.res.in/raghava/abcpred/) predicted 16 meric B-cell epitopes (Saha apan class="Chemical">nd Raghava 2006a, b).

Prediction of T-Cell, CTL Epitopes and Allergic Properties

ProPred-I (http://www.imtech.res.in/raghava/propred1/) (Sipan class="Chemical">ngh and Raghava 2003) was employed for MHC Class-I binding peptide predictionpan> and proposed (http://www.imtech.res.in/raghava/propred/) was used for MHC Class-II binding peptide prediction. Programs were worked at a 4% default threshold by the proteasome and immunoproteasome filters on at 5% threshold (Singh and Raghava 2001). n class="Gene">MHC class I and II predictions were determinpan>ed usinpan>g the Immunpan>e Epitope Database (IEDB) (http://tools.immunpan>eepitope.org/mainpan>/). For predictionpan> of CTL epitopes, “ctlpred” and An class="Chemical">NN methods were used (48). Probability of antigenicity was expected by VaxiJen software at http://www.ddg-pharmfac.net (Doytchinova and Flower 2007). IgE epitopes and n class="Disease">allergic properties were estimated at http://www.imtech.res.in/raghava/algpred/index.html by usinpan>g AlgPred (Saha and Raghava 2006).

Post-modification

n class="Chemical">Serinepan>, n class="Chemical">threonine, and n class="Chemical">tyrosine phosphorylation sites prediction was done using DISPHOS (http://www.dabi.temple.edu/disphos/pred.html) (Iakoucheva et al. 2004) and NetPhos (http://www.cbs.dtu.dk/services/NetPhos/) (Blom et al. 1999). Kinase specific phosphorylation sites were determined by NetPhosK (http://www.cbs.dtu.dk/services/NetPhosK/) (Blom et al. 2004). NetNGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/) (Gupta and Brunak 2002) and GlycoEP (http://www.imtech.res.in/raghava/glycoep/submit.html) were employed for N-glycosylation sites prediction (Chauhan et al. 2013).

Secondary and Tertiary Structure Prediction

To predict secondary apan class="Chemical">nd tertiary structures of core and domain 1 of genotype 1a, SOPMA at (http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_sopma.html) (Geourjon and Deleage 1995), I-TASSER at (http://zhanglab.ccmb.med.umich.edu/I-TASSER) (Roy et al. 2010), PHYRE2server at (http://www.sbg.bio.ic.ac.uk/~phyre2/html) (Kelley and Sternberg 2009), (PS)2-v2 Server at (http://ps2v2.life.nctu.edu.tw) (Chen et al. 2006) were employed. To evaluate the stereochemistry and quality of 3D structures Qmean at (http://swissmodel.expasy.org/qmean/cgi/index.cgi) (Benkert et al. 2008) was used, and the Ramachandaran plot was mapped by Rampage (http://mordred.bioc.cam.ac.uk/~rapper/rampage.php).

The Signal Peptide Prediction

The Signal peptide was predicted by “Signal-BLAST”, and “SignalP 4.1 n class="Chemical">Server”.

Prediction of Epitopes Digestion: Peptide Cutter was Used to Determine Potential Cleavage Sites Cleaved by Proteases

Research Ethics

All data were collected anopan class="Chemical">nymously in accordance with legal requirements regarding data protection and medical confidentiality. Approval from the Faculty n class="Species">Human Research Ethics Committee (Shiraz University of Medical Sciences) was obtained before the commencement of the study.

Results

Mutation and Phylogenic Tree

By consideripan class="Chemical">ng all submitted sequences in n class="Chemical">NCBI GenBank we could not find anclass="Chemical">pan>y sequences related to 2017. Phylogenetic tree for all sequences was shown in Fig. 1. All 2006 sequences were placed in a cluster at the bottom of the tree, and a sequence of 2012 has a high similarity to KF218585.1 (2014). The majority of sequences were clon class="Chemical">ser to 1a and 3a than other referenpan>ce sequenpan>ces.
Fig. 1

Phylogenetic tree based on domain1 sequences and by using neighbor joining method. The phylogenetic tree was constructed by the NJ method. The numbers at the forks show the numbers of occurrences of the repetitive groups to the right out of 100 bootstrap samples. All used reference sequences were showed after accession numbers (1a, 1b, and etc.). Sequences were categorized in five major clusters

Phylogenetic tree based opan class="Chemical">n domain1 sequences and by using neighbor joining method. The phylogenetic tree was constructed by the n class="Chemical">NJ method. The numbers at the forks show the numbers of occurrences of the repetitive groups to the right out of 100 bootstrap samples. All used reference sequences were showed after accession numbers (1a, 1b, and etc.). Sequences were categorized in five major clusters All important mutation positions were listed in Table 2; the majority of mutations happened in 2013 and 2016 samples. n class="Chemical">No mutationpan> was detected inpan>12, 23, 25, 39, 45 positionpan>s.
Table 2

Frequency of all identified mutations in HCV-core domain1 sequences

20062012201320142016Ref
11(T)1(P)1.2%1a(N)
12(K)
23(K)
25(P)––
39(R)
45(G)––
49(T)2(V)11.7%2(P) 2.4%, 5(A) 6.1%, 1(V) 1.2%1(V) 3.5%1(p)1.6%
69(R)
70(R)2(Q)11.7%3(Q) 3.7%, 2(H) 2.4%, 1(P) 1.2%4(Q)14.3%25(Q)42.3%,1(H)1.6%3a,6a (Q)
74(R)
78(Q)1 (R) 3.5%2a,2b (K)
90(G)1(L) 1.2%, 1(S)1.2%
91(C)2(M)11.7%13(M)16.4%, 3(L) 3.7%, 1(F) 1.2%43(M)72.8%, 7(L)11.81b (M); 2a and 5a (L)
102(G)5a (S)
1108(T)47%, 9(N)53%23(N)28.4%, 5(S)6.1%, 53(T)65.4%18(T)64.3%, 8(N)28.57%N (10)17%1b, 1a, 2b(T); 1c(S); 4a, 3a, 6a, 2a, 5a(N)

The majority of mutations happened in amino acid residues 49, 70, 91, 110

Frequency of all identified mutations in n class="Species">HCV-core domainpan>1 sequenpan>ces The majority of mutations happened in amino acid residues 49, 70, 91, 110

Protparam analysis

Protparam results for domain 1 are listed in Table 3. Because of the high percentage of n class="Chemical">basic amino acids, domainpan> 1 is a highly basic peptide (Theoretical pI: 12). The inpan>stability index, an estimate of the stability of a proteinpan> inpan> a test tube, showed that domainpan> 1 is an unpan>stable peptide. Aliphatic inpan>dex, a positive factor for the inpan>crease of thermostability of proteinpan>s, inpan>dicated that this peptide is a thermostable peptide. GRAVY is a hydropath city inpan>dex and inpan>creasinpan>g positive score inpan>dicates a greater hydrophobicity, so this peptide is a hydrophilic peptide.
Table 3

Domain1 physicochemical properties computed by “Protparam”

Amino acid compositionNumberPercentage (%)
Number of amino acids: 117
Molecular weight: 13320.2
Theoretical pI: 12.05
 Ala (A)43.40
 Arg (R)2117.90
 Asn (N)54.30
 Asp (D)21.70
 Cys (C)10.90
 Gln (Q)65.10
 Glu (E)32.60
 Gly (G)1613.70
 Ile (I)21.70
 Leu (L)65.10
 Lys (K)76.00
 Met (M)10.90
 Phe (F)10.90
 Pro (P)1714.50
 Ser (S)76.00
 Thr (T)65.10
 Trp (W)54.30
 Tyr (Y)32.60
 Val(V)43.40
 Total number of negatively charged residues (Asp + Glu)5
 Total number of positively charged residues (Arg + Lys)28
The estimated half-life is
 Mammalian reticulocytes, in vitro30 h
 Yeast, in vivo> 20 h
 Escherichia coli, in vivo> 10 h
 The instability index (II)77.69 unstable
 Aliphatic index40
 Grand average of hydropathicity (GRAVY)− 1.424
Domain1 physicochemical properties computed by “Protparam”

ProtScale Analysis

Hydropathicity analysis by Kyte J. apan class="Chemical">nd Doolittle R.F. method showed that the major part of the peptide had a negative score; the maximum hydropath city score was on n class="Chemical">aa34 (valin) and the minimum hydropath city score was onpan> aa 14 (n class="Chemical">asparagine). Amino acids flexibility predicted by Bhaskaran R Ponnuswamy P.K method indicated that the maximum flexibility was around amino acid 58 (n class="Chemical">proline) and the minpan>imum was arounpan>d aa 95 (n class="Chemical">glycine). Transmembrapan class="Chemical">ne (TM) tendency calculated by Zhao, G., London E. method, showed that the major part of peptide had a negative score, and the maximum transmembrane tendency was on aa34 (valine) and the minimum was on aa10 (lysine). Peptide polarity predicted by Grantham R method showed that the maximum polarity was opan class="Chemical">n amino acid 12 and 13 (lysine and arginine) and the minimum polarity was on aa 34 (valine). http://www.immuneepitope.org online software: Chou and Fasman Beta-Turn Prediction, which is based on the rationale for predicting turns to predict antibody epitopes, showed one high score region, 99–112. Emini Surface Accessibility Prediction, which is based on surface accessibility scale, showed two high score positions (4–20 and 49–61). Karplus and Schulz flexibility scale was used for B-cell predictiopan class="Chemical">n; this method is based on mobility of protein segments on the basis of the known temperature B factors of the a-n class="Chemical">carbons of 31 proteins of knownpan> structure. Results demonstrated two positions with the highest score (50–60 and 5–12). Kolaskar & Tongaopan class="Chemical">nkar Antigenicity method is based on physicochemical properties of amino acid residues and their frequencies of occurrence in experimentally known segmental epitopes to predict antigenic determinants on protein. Results showed five positions of 20–39, 43–49, 63–69, 78–85, and 93–101. Parker Hydrophilicity Prediction method is based opan class="Chemical">n peptide retention times during high-performance liquid chromatography (HPLC) on a reversed-phase column. By this method, two regions were found: 9–16, 51–57. Linear B-cell epitopes were determipan class="Chemical">ned using BepiPred. This method is based on a combination of a hidden Markov model and a propensity scale method. Three regions (1–25, 51–84, and 102–116) were founded by BepiPred analysis.

Bcepred Results

For a combinatiopan class="Chemical">n of all physicochemical properties (hydrophilicity, flexibility/mobility, accessibility, polarity, exposed surface, and turns) for linear B-cell epitope prediction based on physicochemical properties on a non-redundant dataset: Using bcepred online software, n class="Chemical">three regionpan>s (4–22, 47–59, n class="Gene">and 109–115) with the highest combined score were found. Five 16 meric conn class="Chemical">served regions (78, 49, 1, 64 n class="Gene">and 102) were found by ABCpred prediction n class="Chemical">Server (Table 4).
Table 4

16 meric conserved B-cell epitopes regions in HCV-core domain1, predicted by ABCpred online software

RankSequencePositionScore
1QPGYPWPLYGNEGCGW78–930.92
2TRKTSERSQPRGRRQP49–640.9
3MSTNPKPQKKNKRNTN1–160.89
4PIPKARRPEGRTWAQP64–790.86
4GSRPSWGPTDPRRRSR102–1170.86
16 meric conpapan class="Chemical">n class="Chemical">served B-cell epitopes regionpan>s in n class="Species">HCV-core domain1, predicted by ABCpred online software

VaxiJen Prediction

According to a predefined cutoff of VaxiJen program, domain 1 was confirmed as a probable antigen (model: virus and n class="Chemical">threshold: 0.4).

IgE Epitopes

The prediction of allergepan class="Chemical">nic proteins by mapping of IgE epitope, SVM, and hybrid methods showed that domain 1 was not an allergen protein.

T Cell-Epitopes

Regarding T-cell respopan class="Chemical">nses against HCV, previous researches founpan>d some hosts’ human leukocyte antigen (HLA) alleles associations with HCV infection in Iranian patients. We found several epitopes of HLA’s shown in Table 5.
Table 5

HLA predicted epitopes in HCV-core domain1 sequence (genotype 1a) for HLA’s that were determined by previous researches in Iranian patients

HLA typesEpitopes positions
HLA-A11_10
HLA-A229–44, 77–85
HLA-A32–10,29–59, 96–104
HLA-B*35016–14, 27–35, 41–49, 57–65,78–91, 99–116
HLA-B*380129–37, 77–85, 89–97
HLA-Cw*040123–37, 58–65, 78–93
HLA-Cw*070227–35, 73–86
HLA-DQA1*05:012–16,13–27
HLA-DQA1*0201NO
HLA-DQB1*06022–16,17–31, 102–116
HLA-DQB1*030196–104
HLA-G: HLA-G*01:01, HLA-G*01:024–16,8–21, 22–33, 66–79, 100–112
HLA-DRB1*030196–104
HLA-DRB1*030596–104
HLA-DRB1*030996–104
HLA-DRB1*0701No
HLA-DRB1*1134–42
n class="Gene">HLApan> predicted epitopes in HCV-core domain1 sequence (genotype 1a) for HLA’s that were determined by previous researches in Iranian n class="Species">patients Some studies found both n class="Gene">CD4 helper anclass="Chemical">pan>d n class="Gene">CD8 CTL responses against n class="Disease">HCV infection. ctlpred found several epitopes for CTL (Table 6).
Table 6

CTL epitopes in HCV-core domain 1; the high score epitopes are displayed

Peptide RankPositionSequenceScorePrediction
148–56ATRKTSERS1Epitope
280–88GYPWPLYGN1Epitope
32–10STNPKPQKK0.99Epitope
CTL epitopes in n class="Species">HCV-core domain 1; the high score epitopes are displayed

Postmodification

Prediction of n class="Chemical">serine, class="Chemical">pan> class="Chemical">threonine, and tyrosine phosphorylation sites by DISPHOS showed one position (116) in domain1. By “n class="Chemical">NetPhos” software we found 10 phosphorylationpan> sites (Fig. 2), 6 sites for n class="Chemical">serine (53, 56, 99, 103, 106, and 116) 3 sites for threonine (15, 49, and 52) and one site for n class="Chemical">tyrosine (86).
Fig. 2

Phosphorylation sites prediction for domain 1 using “NetPhos” online software. Green lines indicate 6 sites for serine, blues lines show 3 sites for threonine, and one purple line shows tyrosine. All sites with scores above the threshold of 0.5 were considered as phosphorylation sites

Phosphorylation sites predictiopan class="Chemical">n for domain 1 using “NetPhos” online software. Green linclass="Chemical">pan>es indicate 6 sites for serine, blues lines show 3 sites for threonine, and one purple line shows n class="Chemical">tyrosine. All sites with scores above the threshold of 0.5 were considered as phosphorylation sites n class="Chemical">Npan>etPhosK results determined four phosphorylation sites, three threonine amino acids (3, 15, and 49) for protein kinase C and one n class="Chemical">serine (116) for protein kinase A. No glycosylation site was found by NetNGlyc and GlycoEP. Secondary structure prediction for core and domain1 by using SOMPA software was summarized in Table 7 and Fig. 3.
Table 7

Percentage of secondary structures in core and domain1

Alpha helix (Hh)Extended strand (Ee)Beta turn (Tt)Random coil (Cc)
Core39, 20.42%25, 13.09%14, 7.33%113, 59.16%
Domain 1NO19, 16.24%10, 8.55%88, 75.21%
Fig. 3

Secondary structure prediction using SOMPA. Red region is extended strand, blue is the alpha helix, green is beta turn, and purple is the random coil. The majority of core structure belongs to random coil

Percentage of secondary structures in core and domain1 Secondary structure prediction using SOMPA. Red region is extended strand, blue is the alpha helix, green is beta turn, and purple is the random coil. The majority of core structure belongs to random coil SOMPA showed there was no alpha helix structure ipan class="Chemical">n domain1 and the major part of it was the random coil. But the combination of (PS)2-v2 and PHYRE2 showed there was an alpha helix structure in 8–15 region (Figs. 4, 5). All programs displayed extended strand in the 29–36 region.
Fig. 4

Secondary structure prediction using PHYRE2. The result of this tool shows that the majority of the core structure (40%) is alpha helix which is indicated with green helix, also the confidence keys of the predicted structure for these regions are high

Fig. 5

Secondary structure prediction using (PS)2-v2. C coil, H helix, and E extended strand. The majority of core structure contains coil structure

Secondary structure predictiopan class="Chemical">n using PHYRE2. The result of this tool shows that the majority of the core structure (40%) is alpha helix which is indicated with green helix, also the confidence keys of the predicted structure for these regions are high Secondary structure prediction using (PS)2-v2. C coil, H helix, and E extended strand. The majority of core structure contains coil structure 3D structures were determined by all papan class="Chemical">n class="Chemical">three onpan>line software but only structures predicted by I-TASSER were reliable. Final structures (Figs. 6, 7) were validated by Qmean. QMEANscore and Z-score for calculated for core were 0.242 and − 5.43. The scores were not satisfactory but at least provided an overview of the core protein structure. QMEANscore and Z-score for domain 1 were 0.61 and − 1.24 confirming the quality and reliability of the predicted structure.
Fig. 6

3D structure of the core protein using “I-TASSER” program. The selected model had the highest C score and it was qualified by “Qmean”

Fig. 7

3D structure of domain1 using I-TASSER program. The selected model had the highest C score and it was qualified by “Qmean”

3D structure of the core protein using “I-TASn class="Chemical">SER” program. The selected model had the highest C score and it was qualified by “Qmeanclass="Chemical">pan>” 3D structure of domain1 using I-TASn class="Chemical">SER program. The selected model had the highest C score and it was qualified by “Qmeanclass="Chemical">pan>” Ramachandrapan class="Chemical">n plot was assessed by RAMPAGE, and percentages of the favoured region, allowed region, and outlier region for core were 63.0%, 27.5%, and 9.5% respectively (Fig. 8). RAMPAGE results for domain1 showed 61.7% of residues in favored region and 24.3 in allowed region (Fig. 9). Figure 10 showed the showed T cell and B-cell epitopes on the surface of the core protein.
Fig. 8

Ramachandran plot was used to visualize energetically allowed regions for backbone dihedral angles ψ against ϕ of amino acid residues in modeled protein structure (LCC model) for tertiary structure of core protein by RAMPAGE; the majority of amino acids residues were in favored region (119 amino acids) and allowed region (52 amino acids)

Fig. 9

Ramachandran plot was used to visualize energetically allowed regions for backbone dihedral angles ψ against ϕ of amino acid residues in modeled protein structure (LCC model) for tertiary structure of domain1 by RAMPAGE; majority of amino acids residues were in favored region (71 amino acids) and allowed region (28 amino acids)

Fig. 10

A: the position of the B-Cell epitopes (yellow region) on core tertiary structure and B: the T-cell epitopes (yellow region) on core 3D structure

Ramachandran plot was used to visualize energetically allowed regions for backbone dihedral angles ψ against ϕ of amino acid residues in modeled protein structure (LCC model) for tertiary structure of core protein by RAMPAGE; the majority of amino acids residues were in favored region (119 amino acids) and allowed region (52 amino acids) Ramachandran plot was used to visualize energetically allowed regions for backbone dihedral angles ψ against ϕ of amino acid residues in modeled protein structure (LCC model) for tertiary structure of domain1 by RAMPAGE; majority of amino acids residues were in favored region (71 amino acids) and allowed region (28 amino acids) A: the position of the B-Cell epitopes (yellow region) on core tertiary structure and B: the T-cell epitopes (yellow region) on core 3D structure

Core Signal Peptide

Both online tools “Signal-BLAST” and “SignalP 4.1 n class="Chemical">Server” were not able to predict any signpan>al peptide for core proteinpan>.

Cleavage Sites Prediction

The results of “PeptideCutter” prediction were summarized ipan class="Chemical">n Table 8. The prediction was done for all the predicted epitopes. According to the results, the antigenic epitopes that had the lower number of cleavage positions for enzymes were more potential for B cell or T cell epitopes.
Table 8

The results of predicted cleavage positions for 12 common proteases: B-cell, T-cell, and CTL predicted epitopes

PositionsCaspaseChymotrypsinClostripainElastasePepsinProteinase KAsp-NStaphylococcal peptidase IThrombinProlineTrypsin
B-cell epitopes
 78–933(8,9,16)5(4, 7, 9,15, 16)6(4, 6, 8, 9, 12, 16)1(11)1(12)
 49–645 (2, 7, 11, 13, 14)3(1, 4, 6)1(5)1(6)6(2, 3, 7, 11, 13, 14)
 1_161(1)1(13)2(3,15)1(7)4(9, 10, 12, 13)
 64–791(13)3(6, 7, 11)2(5,14)1(12)6(2, 5, 9, 12, 13, 14)1(8)1(9)1(8)3(4, 6, 11)
 102–1171(6)5(3, 12, 13, 14, 16)2(6,9)1(9)1(4)3(12, 14, 16)
CTL epitopes
 48–562(3,8)1(1)4(1, 2, 5, 7)1(6)1(7)3(3, 4 ,8)
 80–882(6,7)3(2, 5, 7)4(2, 4, 6, 7)
 2_101(2)1(6)2(8,9)
T-cell epitopes
 HLA-A1
  1_101(1)1(3)1(7)2(9,10)
 HLA-A2
  29–443(6, 7, 15)3(10, 11, 14)2(2, 5)4(5, 6, 8, 15)7(1, 2, 5, 6, 7, 8, 15)1(10)3(10, 11, 14)
 HLA-A2
  77–851(9)1(1)2(5,8)4(1, 5, 7, 9)
 HLA-A3
  2_101(2)1(6)2(8,9)
 HLA-A3
  29–591(25)3(7,8,16)7(11, 12, 15, 19, 22, 27, 31)4 (3, 6, 18, 20)4(6 7 9 16)12(2, 3, 6, 7, 8, 9, 16, 18, 20, 21, 24, 26,)1(26)1(11)8(11 12 15 19 22 23 27 31)
 HLA-A3
  96–104
 HLA-B*3501
  6_141(8)1(2)4(4, 5, 7, 8)
 HLA-B*3501
  27_351(9)2(5,8)2(8,9)4(4, 5, 8, 9)
 HLA-B*3501
  41–491(4)2(3,7)2(6,8)1(4)4(4 6 8 9)2(3,7)
 HLA-B*3501
  57–653(3 5 6)1(9)4(3, 5, 6, 11)
 HLA-B*3501
  78–912(8,9)3(4, 7, 9)5(4, 6, 8, 9, 12)1(11)1(12)
 HLA-B*3501
  99–1161(9)5(3, 6, 15, 16, 17)2(9, 12)1(12)1(7)3(3, 15, 17)
 HLA-B*3801
  29–373(7, 8, 9)2(3, 6)4(6, 7, 8, 9)6(2 3 6 7 8 9)
 HLA-B*3801
  77–851(9)1(1)2(5,8)4(1, 5, 7, 9)
 HLA-B*3801
  89–973(5, 8, 9)1(6)5(4, 5, 7, 8, 9)5(1, 5, 6, 8, 9)1(1)
 HLA-Cw*0401
  23–373(7, 8, 9)2(3, 6)4(6, 7, 8, 9)6(2, 3, 6, 7, 8, 9)
 HLA-Cw*0401
  58–653(2,4,5)3(2,4,5)
 HLA-Cw*0401
  78–933(8, 9 ,16)5(4, 7, 9, 15, 16)6(4, 6, 8, 9, 12, 16)1(11)1(12)
 HLA-Cw*0702
  27–351(9)2(5, 8)2(8,9)4(4, 5, 8, 9)
 HLA-Cw*0702
  73–863(4, 13, 14)1(2)1(5)4(3 9 12 14)7(3 4 5 9 11 13 14)1(2)
 HLA-DQA1*05:01
  2_161(12)2(2,14)1(6)4(8 ,9, 11, 12)
 HLA-DQA1*05:01
  13–273(1,5,6)1(10)1(12)3(3,10,12)1(8)1(7)3(1,5,11)
 HLA-DQB1*0602
  2_161(12)2(2,14)1(6)4(8 ,9, 11, 12)
 HLA-DQB1*0602
  17–311(4)
 HLA-DQB1*0602
  102–1162(1,2)2(6,15)1(8)4(6, 8, 14, 15)1(3)2(1,7)
 HLA-DQB1*03013(1, 2, 3)2(6, 9)2(1, 2)3(1, 2, 3)2(6, 9)
 HLA-G: HLA-G*01:01, HLA-G*01:02
  4_161(10)1(12)1(4)4(6 7 9 10)
  8_213(6,10,11)1(8)1(13)1(12)5(2, 3, 5 ,6, 10)
  22–332(1,10)1(3)4(1,3,9,10)1(2)
  66–791(11)3(4,5,9)2(3,12)1(10)5(3, 7, 10, 11, 12)1(6)1(7)1(6)3(2,4,9)
  100–1121(8)2(2,5)2(8,11)1(11)1(6)1(2)
 HLA-DRB1*0301
  96–1043(1,2,3)2(6,9)2(1,2)3(1,2,3)2(6,9)
 HLA-DRB1*0305
  96–1043(1,2,3)2(6,9)2(1,2)3(1,2,3)2(6,9)
 HLA-DRB1*0309
  96–1043(1,2,3)2(6,9)2(1,2)3(1,2,3)2(6,9)
 HLA-DRB1*11
  34–422(3,4)2(7,8)1(2)3(2,3,5)4(2,3,4,5)1(7)2(7,8)

The position of each epitope, the number of cleave sites in each epitope as well as the position of the cleave sites in each epitope are mentioned in the table

The results of predicted cleavage positions for 12 commopan class="Chemical">n proteases: B-cell, T-cell, and CTL predicted epitopes The position of each epitope, the pan class="Chemical">number of cleave sites in each epitope as well as the position of the cleave sites in each epitope are mentioned in the table

Discussion

Although emerging bacterial papan class="Chemical">n class="Disease">viral diseases have caused great catastrophes inclass="Chemical">pan> n class="Species">human history which can affect from a small and localized group to millions of n class="Species">people across continents, several vaccine and therapies have been introduced to control them (Dehghani et al. 2014, 2013). Fishman et al. (2009) usipan class="Chemical">ng multivariable logistic regression models ,found 10 HCV-core gene polymorphisms extensively associated with increased HCC risk (36G/C, 209A, 271C/U, 309A/C, 384U, 408U, 435A/C, 465U, 481A, 546A/C) anclass="Chemical">pan>d one significantly linked with decreased HCC risk (78U). Mentioned mutations related to change in domain1 amino acid sequence: N11S/T, K12Silent/N, A25V, G69S, Q70R, M91L, and L102P. All current amino acid changes decreased HCC risk except A25V (78U) (Fishman et al. 2009). In selected sequences, we found that amino acid 11 was T in all sequences except one sequence in 2013 (P) and in 1a (n class="Chemical">N). Positions 12(K) did pan class="Chemical">not show any change; amino acid 25 was P and amino acid 69 was R in all sequences. Amino acid 70 in nearly all sequences was R except in 2 sequences in 2006 (Q), 5 sequences in 2013 (3(Q), n class="Gene">2(H), and 1(P)), 4 sequences in 2014 (Q), in 2016 [25(Q), 1(H) and 2 reference sequences (Q)]. Amino acid 91 ipan class="Chemical">n most sequences was C except 2 sequences in 2006(M), 17 sequences in 2013 (13(M), 3(L), 1(F)),50 sequences in 2016(43(M), 7(L)) and n class="Chemical">three ref sequences, (1b(M), 2a and 5a (L)). In amino acid 102 we did not find any change but in one of the reference sequences, we founpan>d onpan>e change (5a (G to S)). Akuta et al. (2007) employed PCR for detecting substitutiopan class="Chemical">ns of aa 70 and aa 91 in HCV-core gene of genotype 1b by using the mutationpan>-specific primer as an important predictor of hepatocarcinogenesis. For wild samples, aa 70 was arginine (R) and aa 91 was leucine (L) but for mutant aa 70 was n class="Chemical">glutamine(Q)/histidine (H) and aa 91 was methionine (M) (Akuta et al. 2007). Also, Furui et al. (2011) identified aa 70 and aa 91 substitutions among Japanese volunteer blood donors (Furui et al. 2011). In terms of aa 70 substitutiopan class="Chemical">ns, we recognized 2 glutamine substitutions in 2006 sequenclass="Chemical">pan>ces and 3 glutamine, 2 histidines, one n class="Chemical">proline in 2013 sequences; also 4 glutamine substitutions in 2014 sequences, and 25 glutamine, and 1 histidine in 2016. We found several methionine residues in aa 91 in 2006, 2014, and 2016. Ogata et al. (2002) compared sequepan class="Chemical">nces of the core protein of Subtype 1b HCV strains obtained from class="Chemical">pan> class="Species">patients with and without HCC and found some amino acid mutation sites (Ogata et al. 2002). K23Q, Q70R, and T110M substitutions were found by Ogata et al. (2002). In comparison with our results, in all sequences, aa 23 was K, in the majority of sequences aa 70 was R and in 34 sequences it was Q. In aa 110 we did not find any methionine (Ogata et al. 2002). Akuta et al. (2010) confirmed the role of papan class="Chemical">n class="Chemical">Gln70 (or class="Chemical">pan> class="Chemical">His70) in the efficacy of triple therapy and sustained a virological response, the patient with both genotype non-TT and Gln70 (His70) had the worst sustained virological response. Also, Akuta et al. (2011) by following up twenty-six patients determined the role of Gln70 (His70) substitution in the development of HCC They suggested detection of aa substitutions in the core region before antiviral therapy (Akuta et al. 2010, 2011). Alestig et al. (2011) showed substitution in aa 70 of the core was related to treatment response, but that was less important than n class="Gene">IL28B polymorphism. Inpan> our study, 37 sequenpan>ces had n class="Chemical">Gln70 (or His70) substitution (Alestig et al. 2011). Tokita et al. (2000) approved the role of n class="Species">HCVpan>-core region (Thr49Pro) to reduce the fluorescence enzyme immunoassay (FEIA) sensitivity. We found 2 sequences in 2013 and one in 2016 with T to P substitutions (Tokita et al. 2000). Findipan class="Chemical">ngs of Horie et al. (1999) indicated that alteration from glycine to serine at core codon 45 was dominant in noncancerous liver portions rather than in cancerous liver portions and sera from HCC patients (Horie et al. 1999). Our results did not show any glycine to serine mutation in aa 45 and in all sequences, it was glycine. Idrees and Ashfapan class="Chemical">q (2013) by using molecular docking software, reported interactions of amino acid residues arginine 149, arginine 39, arginine 74, and arginine 78 in HCV-core protein and Leu44, Ala71, Ser76 and Pro97 in CXCL6. This finding clues to understanding HCV pathogenesis. Any change in these positions can relate to HCV Infection and HCC. Our results showed no alteration in aa 39 and 74, and in aa 78 just one sequence was glutamine to arginine (Idrees and Ashfaq 2013). Using a combipan class="Chemical">nation of predicted B-cell antibody epitopes by all methods on the immune epitope website and also considering bcepred and ABCpred prediction ,we could define n class="Chemical">three major epitopes (4–20, 50–60, n class="Gene">and 100–112) for domain 1. Ferroni et al. (1993) by using the algorithm of Jameson and Wolf identified four epitopes in n class="Species">HCV-core proteinpan> (7–21, 31–45, 49–63, anpan>d 99–113). Harase et al. (1995) analyzed the respopan class="Chemical">nse to n class="Species">HCV-core protein inclass="Chemical">pan> n class="Species">mice and found a major B cell epitope (21–40). Pirisi et al. (1995) analyzed papan class="Chemical">n class="Chemical">Sera from 97 class="Chemical">pan> class="Species">HCV infected patients and found three 15-mer peptides as antigens in an enzyme immunoassay. They concluded that anti-R15P (50–64, RKTSERSQPRGRRQP) as a potent antigen might help to identify a subgroup at higher risk to develop HCC (Pirisi et al. 1995). Also, a study on papan class="Chemical">n class="Species">HCV positive blood donclass="Chemical">pan>or by Lechmann et al. (1996) determined a region (aa 1–24) of domain1 that bounpan>d the antibodies from the sera of all patients and showed a great potential for detection of HCV infection by using serological B-Cell responses tests. Comparison of our results with previous studies revealed that all predicted epitopes ipan class="Chemical">n our research have a good potential for future studies of the immune response against n class="Disease">HCV infection, and are useful for recognition of all kinds of n class="Disease">HCV infections. Gededzha et al. (2014) used several bioinformatics tools to predict papan class="Chemical">n class="Gene">HLA class I anclass="Chemical">pan>d n class="Gene">HLA class II in n class="Species">HCV genotype 5a. They found three T-cell epitopes of NS3, NS4B, and NS5B. Some n class="Gene">HLApan> class II alleles were found in Iranian patients by Samimi-Rad et al. (2015); DRB1*0301, DQA1*0501, DQB1*0201, DRB1*1101, and DQB1*0301 were demonstrated in n class="Species">patients with HCV clearance, and DRB1*0701, DQA1*0201, DQB1*0602, DRB1*0301, DRB1*11, and DQB1*0201 occurred more frequently in chronic patients (Samimi-Rad et al. 2015). Khorrami et al. (2015) found a relatiopan class="Chemical">nship between HLA-G, IL-10, and response to combined therapy in HCV positive patients. They concluded that HLA-G, and IL-10 have a significant role in response to therapy with IFN-α2α and ribavirin. Also, n class="CellLine">HLA-A01 and n class="Gene">HLA-B38 were determined as important alleles associated with Peg-IFN plus n class="Chemical">ribavirin therapy in Egyptian patients by Farag et al. (2013). Pourhassan et al. (2014) found several n class="Gene">HLA alleles associated with n class="Species">HCV in Iranian patients (2011–2013). A2, A3, B35, B38, BW4, CW4and CW7 were the most frequent alleles found by this group. In accordapan class="Chemical">nce with the above-mentioned studies, we collected HLA alleles associated with HCV infection, and by employing in-silico analysis we established numerous T-cell epitopes for domain1 that can be helpful for future studies to design effective vaccine against HCV genotype 1a, and can provide benefit data for better understanding the role of domain1 in immune response. Many researchers have proved broader CTL respopan class="Chemical">nses to n class="Disease">HCV infection and the usefulnpan>ess of CTL epitopes mapping to develop therapeutic interventions or vaccines (Sabet et al. 2014; Saeedi et al. 2014; Jazayeri and Carman 2005; Arashkia et al. 2011). In our research, we utilized reliable software to predict CTL epitopes and extracted data that can be useful for vaccine development studies. By consideripan class="Chemical">ng results of phosphorylation sites prediction by 3 programs, we concluded that 3 sites (15, 49, and 116) were the main phosphorylation sites in domain 1. Aminclass="Chemical">pan>o acid 116 is a n class="Chemical">serine that located in n class="Chemical">Arg-Arg-Arg-Ser-Arg region; this region was similar to the usual target sequence for protein kinase A [Arg-Arg-X-Ser/Thr-X]. Two threonine amino acid residues (15, 49) were calculated as protein kinase c target sites where this kinase acts through the phosphorylation of hydroxyl groups of amino acid residue. Previous studies indicated that core protein is phosphorylated by PKA and PKC. Core phosphorylation regulates the suppressive activity of papan class="Chemical">n class="Species">HCV-core proteinclass="Chemical">pan> on HBV gene replication and expression. Also, it has been shownpan> that phosphorylation in core relates to the nuclear localization of the core protein. They demonstrated three serine residues (Ser-53, Ser-116, and Ser-99) as the potential phosphorylated sites in core protein, that were similar to NetPhos software results in our research (Yassin 2001; Shih et al. 1995; Lu and Ou 2002). Secondary structure predictiopan class="Chemical">n indicated that the majority of domain1 was the random coil, and all B-cell epitopes and important mutations placed on random coil structure. Tertiary structures were designed by n class="Chemical">three significant and reliable onlinpan>e programs, but just one of them provided a reliable and high-quality proteinpan> structure model for domainpan>1. The quality and reliability of models were confirmed by QMEAn class="Chemical">N and RAMPAGE software. By examinipan class="Chemical">ng all the predictions core epitopes with and without signal peptide, we found out that there is no difference between these two different strategies of analysis (Pene et al. 2009; Tn class="Chemical">argett-Adams et al. 2008; Ma et al. 2007; Okamoto et al. 2008; Oehler et al. 2012). Based on previous studies core protein has a C terminal signal peptide (170–191) and because the focus of our study was on domain 1, it was expected that the deletion of this region could not affect the epitope perdition results. Digestion analysis to predict possible proteases was shown that each epitope can be digested by at least 5 selected proteases which can have a significant effect on the reduction of the half-life of epitopes.

Conclusion

Finally our ipan class="Chemical">nvestigations in this research provided comprehensive data about frequent mutations in domain1, and as a first report can be useful for future study about significant mutations and their role in therapeutic pathway and response to antiviral therapy for Iranian n class="Species">patients. Also, identification of domain1 properties provides practical information for domain1 cloning and more researches.
  71 in total

1.  Prediction of continuous B-cell epitopes in an antigen using recurrent neural network.

Authors:  Sudipto Saha; G P S Raghava
Journal:  Proteins       Date:  2006-10-01

2.  Association between Human Leukocyte Antigen class-I and hepatitis C: the first report in Azeri patients.

Authors:  Abolfazl Pourhassan
Journal:  Pak J Biol Sci       Date:  2014-06

3.  Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.

Authors:  Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Med Virol       Date:  2011-06       Impact factor: 2.327

4.  Phosphorylation of hepatitis C virus core protein by protein kinase A and protein kinase C.

Authors:  Wen Lu; Jing-hsiung Ou
Journal:  Virology       Date:  2002-08-15       Impact factor: 3.616

5.  Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma.

Authors:  Satoshi Ogata; Motoko Nagano-Fujii; Yonson Ku; Seitetsu Yoon; Hak Hotta
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

6.  Reactivity to B cell epitopes within hepatitis C virus core protein and hepatocellular carcinoma.

Authors:  M Pirisi; C Fabris; P Toniutto; D Vitulli; G Soardo; E Falleti; F Gonano; P Ferroni; V Gasparini; E Bartoli
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

7.  Humoral immune response in acute hepatitis C virus infection.

Authors:  Dale M Netski; Tim Mosbruger; Erik Depla; Geert Maertens; Stuart C Ray; Robert G Hamilton; Stacy Roundtree; David L Thomas; Jane McKeating; Andrea Cox
Journal:  Clin Infect Dis       Date:  2005-07-22       Impact factor: 9.079

8.  Core as a novel viral target for hepatitis C drugs.

Authors:  Arthur Donny Strosberg; Smitha Kota; Virginia Takahashi; John K Snyder; Guillaume Mousseau
Journal:  Viruses       Date:  2010-08-20       Impact factor: 5.818

9.  Improved method for predicting linear B-cell epitopes.

Authors:  Jens Erik Pontoppidan Larsen; Ole Lund; Morten Nielsen
Journal:  Immunome Res       Date:  2006-04-24

10.  (PS)2: protein structure prediction server.

Authors:  Chih-Chieh Chen; Jenn-Kang Hwang; Jinn-Moon Yang
Journal:  Nucleic Acids Res       Date:  2006-07-01       Impact factor: 16.971

View more
  2 in total

1.  Designing a conserved peptide-based subunit vaccine against SARS-CoV-2 using immunoinformatics approach.

Authors:  Elijah Kolawole Oladipo; Ayodeji Folorunsho Ajayi; Olugbenga Samson Onile; Olumuyiwa Elijah Ariyo; Esther Moradeyo Jimah; Louis Odinakaose Ezediuno; Oluwadunsin Iyanuoluwa Adebayo; Emmanuel Tayo Adebayo; Aduragbemi Noah Odeyemi; Marvellous Oluwaseun Oyeleke; Moyosoluwa Precious Oyewole; Ayomide Samuel Oguntomi; Olawumi Elizabeth Akindiya; Victoria Oyetayo Aremu; Dorcas Olubunmi Aboderin; Julius Kola Oloke
Journal:  In Silico Pharmacol       Date:  2021-01-06

2.  Reciprocal Inhibition of Immunogenic Performance in Mice of Two Potent DNA Immunogens Targeting HCV-Related Liver Cancer.

Authors:  Juris Jansons; Dace Skrastina; Alisa Kurlanda; Stefan Petkov; Darya Avdoshina; Yulia Kuzmenko; Olga Krotova; Olga Trofimova; Ilya Gordeychuk; Irina Sominskaya; Maria Isaguliants
Journal:  Microorganisms       Date:  2021-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.